{"denoms":[{"counts":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"67"},{"groupId":"BG003","value":"212"}],"units":"Participants"}],"groups":[{"description":"ciprofloxacin: Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro® 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.\n\nofloxacin: Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.","id":"BG000","title":"Ciprofloxacin or Ofloxacin"},{"description":"trimethoprim-sulfamethoxazole: Begin oral Trimethoprim-sulfamethoxazole when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \\[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\\] every 12 hours for two months..","id":"BG001","title":"TMP-SMX"},{"description":"No prophylaxis: The patient will receive no prophylactic antibiotics.","id":"BG002","title":"Observation"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"32.4","upperLimit":"86.0","value":"63.7"},{"groupId":"BG001","lowerLimit":"36.7","upperLimit":"85.7","value":"62.6"},{"groupId":"BG002","lowerLimit":"36.7","upperLimit":"89.3","value":"65.0"},{"groupId":"BG003","lowerLimit":"32.4","upperLimit":"89.3","value":"63.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"79"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"133"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"160"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"52"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"67"},{"groupId":"BG003","value":"212"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"28"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"184"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"Infection in last 6 months","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"34"}]}],"title":"Melphalan, Prednisone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"22"}]}],"title":"VBMCP"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"63"}]}],"title":"Vincristine, Adriamycin, Dexamethasone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"93"}]}],"title":"Other"}],"description":"VBMCP=vincristine, carmustine, melphalan, cyclophosphamide, and prednisone","paramType":"NUMBER","title":"Chemotherapy regimen","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"3","value":"1.0"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"4","value":"1.1"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"4","value":"0.8"},{"groupId":"BG003","lowerLimit":"0","upperLimit":"4","value":"1.0"}]}]}],"description":"ECOG PERFORMANCE STATUS: Used by doctors and researchers to assess how a patient's disease is progressing.\n\n0: Fully active, able to carry on pre-disease performance\n\n1. Restricted in physically strenuous activity but ambulatory; able to carry out work of a light or sedentary nature\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours\n3. Capable of limited selfcare, confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on selfcare. Confined to bed or chair\n5. Dead","dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Eastern Cooperative Oncology Group (ECOG) performance status","unitOfMeasure":"units on a scale"}],"populationDescription":"Patients with symptomatic and untreated MM receiving chemotherapy without an active infection during the 7 days prior to initiation of chemotherapy and off antibiotics for the prior 7 days were eligable for this study. They were required to receive myelosuppressive and/or immunosuppressive chemotherapy, and were randomized on a 1:1 basis."}